Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3435-3438

  Zheng, Pinguan ^a   Lieberman, Brian P ^a   Choi, Seok Rye ^b   Plöessl, Karl ^a   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Dihydrotetrabenazine; Parkinson's disease; Positron emission tomography; Vesicular monoamine transporter

Indexed keywords

DIHYDROTETRABENAZINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; NONHUMAN; PARKINSON DISEASE; RAT;

ANIMALS; CORPUS STRIATUM; CRYSTALLOGRAPHY, X-RAY; DIAGNOSTIC IMAGING; FLUORINE RADIOISOTOPES; LIGANDS; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RATS; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

RATTUS;

EID: 79956140210     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.113     Document Type: Article

References (38)

1. G. Zheng, L.P. Dwoskin, and P.A. Crooks The AAPS Journal 8 2006 E682
2. J.D. Erickson, L.E. Eiden, and B.J. Hoffman Proc. Natl. Acad. Sci. U.S.A. 89 1992 10993
3. Y. Liu, D. Peter, A. Roghani, S. Schuldiner, G.G. Prive, D. Eisenberg, N. Brecha, and R.H. Brecha Cell 70 1992 539
4. J. Erickson, and L. Eiden J. Neurochem. 61 1993 2314
5. A. Brossi, H. Lindlar, M. Walter, and O. Schnider Helv. Chim. Acta 41 1958 119
6. M.R. Hayden, B.R. Leavitt, U. Yasothan, and P. Kirkpatrick Nat. Rev. Drug Disc. 8 2009 17
7. N.I. Bohnen, R.L. Albin, R.A. Koeppe, K.A. Wernette, and M.R. Kilbourn J. Cereb. Blood Flow Metab. 26 2006 1198
8. M.R. Kilbourn Nucl. Med. Biol. 24 1997 615
9. R.A. Koeppe, K.A. Frey, T.M. Vander Borght, A. Karlamangla, D.M. Jewett, L.C. Lee, M.R. Kilbourn, and D.E. Kuhl J. Cereb. Blood Flow Metab. 16 1996 1288
10. FP-DTBZ as pancreas imaging agent, see: R. Goswami, D.E. Ponde, M.-P. Kung, C. Hou, M.R. Kilbourn, and H.F. Kung Nucl. Med. Biol. 33 2006 685
11. M.R. Kilbourn, B. Hockley, L. Lee, C. Hou, R. Goswami, D.E. Ponde, M.-P. Kung, and H.F. Kung Nucl. Med. Biol. 34 2007 233
12. M.-P. Kung, C. Hou, R. Goswami, D.E. Ponde, M.R. Kilbourn, and H.F. Kung Nucl. Med. Biol. 34 2007 239
13. N. Okamura, V.L. Villemagne, J. Drago, S. Pejoska, R.K. Dhamija, R.S. Mulligan, J.R. Ellis, U. Ackermann, G. O'Keefe, G. Jones, H.F. Kung, M.J. Pontecorvo, D. Skovronsky, and C.C. Rowe J. Nucl. Med. 51 2010 223
14. FP-DTBZ as pancreas imaging agent, see: H.F. Kung, B.P. Lieberman, Z.-P. Zhuang, S. Oya, M.-P. Kung, S.R. Choi, K. Ploessl, E. Blankemeyer, C. Hou, D. Skovronsky, and M. Kilbourn Nucl. Med. Biol. 35 2008 825
15. M.-P. Kung, C. Hou, B.P. Lieberman, S. Oya, D.E. Ponde, E. Blankemeyer, D. Skovronsky, M.R. Kilbourn, and H.F. Kung J. Nucl. Med. 49 2008 1171
16. H.-H. Tsao, K.-J. Lin, J.-H. Juang, D.M. Skovronsky, T.-C. Yen, S.-P. Wey, and M.-P. Kung Nucl. Med. Biol. 37 2010 413
17. Amino TBZ, see: D.J. Canney, M.-P. Kung, and H.F. Kung Nucl. Med. Biol. 22 1995 527
18. L. Zhu, J. Liu, and H.F. Kung Bioorg. Med. Chem. Lett. 19 2009 5026
19. Iodovinyl TBZ, see: D.J. Canney, Y.Z. Guo, M.-P. Kung, and H.F. Kung J. Labelled Compd. Rad. 33 1993 355
20. M.-P. Kung, D.J. Canney, D. Frederick, Z. Zhuang, J.J. Billings, and H.F. Kung Synapse 18 1994 225
21. Racemic synthesis, see: H.T. Openshaw, and N.J. Whittaker Chem. Soc. 1963 1449
22. Q. Yu, W. Luo, J. Deschamps, H.W. Holloway, T. Kopajtic, J.L. Katz, A. Brossi, and N.H.A.C.S. Greig Med. Chem. Lett. 1 2010 105
23. Asymmetric synthesis, see: M.J. Rishel, K.K.D. Amarasinghe, S.R. Dinn, and B.F. Johnson J. Org. Chem. 74 2009 4001
24. S.-M. Paek, N.-J. Kim, D. Shin, J.-K. Jung, J.-W. Jung, D.-J. Chang, H. Moon, and Y.-G. Suh Chem. Eur. J. 16 2010 4623
25. A.W. Johnson, E. Markham, and R. Price Org. Syn. 42 1962 75
26. T.B. Ayed, and H. Amri Synthetic Commun. 25 1995 3813
27. See the Supplementary data for the details.
28. 4. The solvent was removed in vacuo. Crude product was triturated with acetone to provide 0.98 g of 4b as single diastereomer and 1.0 g of 4b as diastereomeric mixture (d.r.: 4:1), 90% combined yield.
29. B. Loubinoux, G. Coudert, and G. Guillaumet Synthesis 1980 638
30. M.R. Kilbourn, L.C. Lee, M.J. Heef, and D.M. Jewett Chirality 9 1997 59
31. 2, 2% MeOH/DCM to 5% MeOH/DCM) to provide 10a as foam (113 mg, 93% yield).
32. Several conditions were employed in the alkylation of 2,4-pentadione. (a) Ref. 14. (b) Shih, C. C. Y.; Shi, Q.; Wang, H.-K.; Su, C.-Y. PCT Int. Appl. WO 2008085984 A1, 2008; Scifinder Scholar AN 2008: 857452.
33. 2, 20% EtOAc/Hexanes to 30% EtOAc/Hexanes) to provide 18a as white solid (38.4 mg, 58% yield). Compound 18a was converted to 4c according to Ref. 17.
34. A.R. Battersby, H.T. Openshaw, and H.C.S. Wood J. Chem. Soc. 1953 2463
35. J. Bosch, A. Domingo, and A. Linares J. Org. Chem. 48 1983 1075
36. Z. Horii, M. Ikeda, M. Hanaoka, M. Yamauchi, Y. Tamura, S. Saito, T. Tanaka, K. Kotera, and N. Sugimoto Chem. Pharm. Bull. 15 1967 1633
37. CCDC 799803 contains the supplementary crystallographic data for this Letter. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/ data-request/cif, or by emailing data-request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
38. A. Pletscher, A. Brossi, and K.F. Gey Int. Rev. Neurobiol. 4 1962 275